Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs eMed

AM Rx
Graded #490

Lower grade

vs+7.5
eMed
Graded #398

Higher grade

The verdict

eMed takes it — 57.4/100 to 49.9/100.

eMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. eMed is a digital health platform best known for at-home diagnostics that now runs a clinician-supported GLP-1 weight management program.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +6
51
45
Dose & formulationAM Rx +25
65
40
Clinical oversighteMed +42
41
83
Labs & monitoringeMed +16
49
65
FulfillmenteMed +4
58
62
Contract termseMed +35
20
55
AM Rx · left bareMed · right bar

The numbers

MetricAM RxeMed
WeighScore49.9/10057.4/100
GradeCC
Scorecard rank#490#398
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #490 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
eMed

Graded #398 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s (semaglutide and tirzepatide)
  • At-home blood collection makes lab work convenient
  • Clinician review and ongoing side-effect plus adherence support
  • Works with CVS Caremark so eligible employees can buy through benefits
  • Established digital health company with national scale

Where it loses points

  • Distributed mainly via employers, with limited direct cash-pay access
  • No public transparent monthly price for individuals
  • Eligibility and subsidy depend on what the employer chooses to cover
  • Best suited to workforces, not casual self-pay shoppers

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard